JP7627348B2 - 分析物および無細胞ヘモグロビン濃度に基づく干渉臨界の決定 - Google Patents
分析物および無細胞ヘモグロビン濃度に基づく干渉臨界の決定 Download PDFInfo
- Publication number
- JP7627348B2 JP7627348B2 JP2023538715A JP2023538715A JP7627348B2 JP 7627348 B2 JP7627348 B2 JP 7627348B2 JP 2023538715 A JP2023538715 A JP 2023538715A JP 2023538715 A JP2023538715 A JP 2023538715A JP 7627348 B2 JP7627348 B2 JP 7627348B2
- Authority
- JP
- Japan
- Prior art keywords
- cell
- concentration
- free hemoglobin
- analyte concentration
- interference threshold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000001554 Hemoglobins Human genes 0.000 title claims description 457
- 108010054147 Hemoglobins Proteins 0.000 title claims description 457
- 239000012491 analyte Substances 0.000 title claims description 342
- 239000007788 liquid Substances 0.000 claims description 118
- 238000012545 processing Methods 0.000 claims description 58
- 210000004369 blood Anatomy 0.000 claims description 51
- 239000008280 blood Substances 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 29
- 210000003743 erythrocyte Anatomy 0.000 claims description 23
- 238000004590 computer program Methods 0.000 claims description 20
- 230000002452 interceptive effect Effects 0.000 claims description 19
- 229910001414 potassium ion Inorganic materials 0.000 claims description 17
- 239000011148 porous material Substances 0.000 claims description 13
- 239000012530 fluid Substances 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 9
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims description 7
- 238000004891 communication Methods 0.000 claims description 5
- 239000000523 sample Substances 0.000 description 172
- 230000008901 benefit Effects 0.000 description 31
- 238000005259 measurement Methods 0.000 description 31
- 230000008859 change Effects 0.000 description 22
- 230000000694 effects Effects 0.000 description 17
- 206010018910 Haemolysis Diseases 0.000 description 14
- 230000008588 hemolysis Effects 0.000 description 14
- 208000019025 Hypokalemia Diseases 0.000 description 13
- 208000024896 potassium deficiency disease Diseases 0.000 description 13
- 238000001514 detection method Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 208000002682 Hyperkalemia Diseases 0.000 description 8
- 230000003804 effect on potassium Effects 0.000 description 8
- 238000013102 re-test Methods 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- -1 O2 Chemical compound 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 239000002572 performance enhancing substance Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/492—Determining multiple analytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Ecology (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025010348A JP2025069231A (ja) | 2020-12-22 | 2025-01-24 | 分析物および無細胞ヘモグロビン濃度に基づく干渉臨界の決定 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20216633.6 | 2020-12-22 | ||
| EP20216633 | 2020-12-22 | ||
| PCT/EP2021/086911 WO2022136327A1 (en) | 2020-12-22 | 2021-12-20 | Determining interference criticality based on analyte and cell-free hemoglobin concentrations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025010348A Division JP2025069231A (ja) | 2020-12-22 | 2025-01-24 | 分析物および無細胞ヘモグロビン濃度に基づく干渉臨界の決定 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024500231A JP2024500231A (ja) | 2024-01-05 |
| JP7627348B2 true JP7627348B2 (ja) | 2025-02-05 |
Family
ID=73856885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023538715A Active JP7627348B2 (ja) | 2020-12-22 | 2021-12-20 | 分析物および無細胞ヘモグロビン濃度に基づく干渉臨界の決定 |
| JP2025010348A Pending JP2025069231A (ja) | 2020-12-22 | 2025-01-24 | 分析物および無細胞ヘモグロビン濃度に基づく干渉臨界の決定 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025010348A Pending JP2025069231A (ja) | 2020-12-22 | 2025-01-24 | 分析物および無細胞ヘモグロビン濃度に基づく干渉臨界の決定 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240044918A1 (https=) |
| EP (1) | EP4267972A1 (https=) |
| JP (2) | JP7627348B2 (https=) |
| CN (1) | CN116868058A (https=) |
| WO (1) | WO2022136327A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230333013A1 (en) * | 2022-04-15 | 2023-10-19 | Instrumentation Laboratory Co. | Fluid testing system |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014516944A (ja) | 2011-04-29 | 2014-07-17 | ブリストル−マイヤーズ スクイブ カンパニー | Ｉｐ１０抗体の用量漸増計画 |
| JP2018533011A (ja) | 2015-11-18 | 2018-11-08 | ラジオメーター・メディカル・アー・ペー・エス | 流体中の検体を光学的に検出するための多孔質ミラー |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6623972B2 (en) * | 2000-06-09 | 2003-09-23 | Bayer Corporation | Automated method for detecting, quantifying and monitoring exogenous hemoglobin in whole blood, plasma and serum |
| PL2356465T3 (pl) * | 2008-11-13 | 2015-04-30 | Beckman Coulter Inc | Sposób korekcji interferencji cząsteczkowej przy oznaczaniu hemoglobiny |
| US12064765B2 (en) * | 2018-08-06 | 2024-08-20 | Siemens Healthcare Diagnostics Inc. | Method and device for determining the concentration of analytes in whole blood |
-
2021
- 2021-12-20 CN CN202180094309.XA patent/CN116868058A/zh active Pending
- 2021-12-20 EP EP21840931.6A patent/EP4267972A1/en active Pending
- 2021-12-20 US US18/258,592 patent/US20240044918A1/en active Pending
- 2021-12-20 JP JP2023538715A patent/JP7627348B2/ja active Active
- 2021-12-20 WO PCT/EP2021/086911 patent/WO2022136327A1/en not_active Ceased
-
2025
- 2025-01-24 JP JP2025010348A patent/JP2025069231A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014516944A (ja) | 2011-04-29 | 2014-07-17 | ブリストル−マイヤーズ スクイブ カンパニー | Ｉｐ１０抗体の用量漸増計画 |
| JP2018533011A (ja) | 2015-11-18 | 2018-11-08 | ラジオメーター・メディカル・アー・ペー・エス | 流体中の検体を光学的に検出するための多孔質ミラー |
Non-Patent Citations (2)
| Title |
|---|
| A M Dupuy，Determination of hemolysis cut-offs for biochemical and immunochemical analytes according to their value，Clin Chem Lab Med.，2020年07月28日，58(8)，pp1232-1241，doi: 10.1515/cclm-2019-1228 |
| JAY DW，Characterization and mathematical correction of hemolysis interference in selected Hitachi 717 assays，Clin Chem.，1993年09月，39(9)，pp1804-1810 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240044918A1 (en) | 2024-02-08 |
| EP4267972A1 (en) | 2023-11-01 |
| WO2022136327A1 (en) | 2022-06-30 |
| CN116868058A (zh) | 2023-10-10 |
| JP2024500231A (ja) | 2024-01-05 |
| JP2025069231A (ja) | 2025-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Najat | Prevalence of pre-analytical errors in clinical chemistry diagnostic labs in Sulaimani city of Iraqi Kurdistan | |
| US10709392B2 (en) | Sensor fault detection using analyte sensor data pattern comparison | |
| Allardet-Servent et al. | Point-of-care versus central laboratory measurements of hemoglobin, hematocrit, glucose, bicarbonate and electrolytes: a prospective observational study in critically ill patients | |
| Harenberg et al. | Detecting anti-IIa and anti-Xa direct oral anticoagulant (DOAC) agents in urine using a DOAC dipstick | |
| Bloom et al. | A comparison of measurements of sodium, potassium, haemoglobin and creatinine between an Emergency Department-based point-of-care machine and the hospital laboratory | |
| Prasad et al. | Morphologic and cytomorphometric analysis of exfoliated buccal mucosal cells in diabetes patients | |
| JP2025069231A (ja) | 分析物および無細胞ヘモグロビン濃度に基づく干渉臨界の決定 | |
| Nass et al. | Hemoglobin point-of-care testing in rural Gambia: Comparing accuracy of HemoCue and Aptus with an automated hematology analyzer | |
| Kos et al. | Validation of a new generation POCT glucose device with emphasis on aspects important for glycemic control in the hospital care. | |
| JP2022523110A (ja) | バイオマーカー分析に基づいて将来の皮膚傾向を視覚化するためのシステムおよび方法 | |
| Tan et al. | Impact of delta check time intervals on error detection capability | |
| Schrot et al. | Evaluation of inaccuracies in the measurement of glycemia in the laboratory, by glucose meters, and through measurement of hemoglobin A1c | |
| WO2018017199A1 (en) | System and method for optical whole blood hemolysis detection | |
| Smellie | What is a significant difference between sequential laboratory results? Calf muscle pain can indicate localised vasculitis | |
| Westgard et al. | Intelligent Quality Management 2 with IntraSpect™ technology for quality control of GEM® Premier™ 5000 blood gas analyzers—A novel application of the patient sample as its own control | |
| Daya et al. | Detecting hyperglycemia using biomarkers versus continuous glucose monitoring | |
| Santos et al. | Evaluation of Three Human‐Use Glucometers for Blood Glucose Measurement in Dogs | |
| Pham et al. | Impact of hematocrit levels on the accuracy of specific blood glucose meters: A hospital‐based study | |
| Rojekar et al. | Assessment of analytical performance of glucose meter in pediatric age group at tertiary care referral hospital | |
| EP3224608B1 (en) | Verifying operation of a meter | |
| Watson | Analytical investigations closer to the patient. | |
| Solutions et al. | Accelerated Orphan Drug Approval: Surrogate Endpoints | |
| CN106990232B (zh) | 血液试剂分析系统以及分析方法 | |
| Chang et al. | Performance analysis of the OneTouch® UltraVue™ blood glucose monitoring system | |
| Shapiro | Developing a Low-Cost Spectrophotometric System to Detect and Monitor Newborn Conditions at the Point-of-Care in Low-Resource Settings |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230822 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240424 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240502 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240802 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241105 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241225 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250124 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7627348 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |